4.40
+1.85%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Zhejiang Taimei Medical Technology Co
Its shares trade on HKEX under the ticker 2576.HK. It has been listed since 8 October 2024. In the fiscal year to 31 December 2025, it reported revenue of CN¥581.4m and a net loss of CN¥48.6m. At that date it held total assets of CN¥1.81bn and shareholders' equity of CN¥1.31bn.
Zhejiang Taimei Medical Technology Co Ltd is a CN-based company operating in Life Sciences Tools & Services industry. The company is headquartered in Jiaxing, Zhejiang. The company went IPO on 2024-10-08. Zhejiang Taimei Medical Technology Co Ltd is a China-based company mainly engaged in the provision of digital solutions for the research and development and commercialisation of pharmaceutical and medical device. The firm mainly designs and provides industry-specific software and digital services to a variety of stakeholders in the pharmaceutical and medical device industry. The firm's cloud-based software mainly provides software as a service (SaaS) products and customized products as well as related technical support, including TrialOS, a digital collaboration platform for the research and development of pharmaceutical and medical device, and PharmaOS, a digital collaboration platform for pharmaceutical and medical device commercialization. The firm's digital services mainly include digital clinical research services and independent reading center (IRC) services. The firm principally conducts its businesses in domestic and overseas markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 8 Oct 2024
- Employees
- 783
- Website
- taimei.com ↗
Leadership
Pay as last reported
- Mr. Zhao LuExecutive Chairman, General Manager, since 2016CN¥20.8m
- Mr. Chengwen JiangChief Financial Officer
- Mr. Yiming LuChief Technology Officer, Executive Director, since 2024CN¥426,000
- Mr. Yufei HuangExecutive Director and Head of the Operations Assurance Division, since 2015CN¥376,000
- Mr. Dong MaExecutive Director and Chief Product OfficerCN¥509,000
- Ms. Xiaomei NiExecutive Director, Legal Director and Board Secretary, since 2018CN¥780,000
- Mr. Hongwei ZhangExecutive Director and Head of Digital Marketing DivisionCN¥378,000
- Mr. Che Wai FungNon-Executive Independent DirectorCN¥54,000
- Dr. Xiao JiangNon-Executive Independent DirectorCN¥45,000
- Dr. Zhiguo LiNon-Executive Independent DirectorCN¥45,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Zhejiang Taimei Medical Technology employs 783 full-time employees in Jiaxing, China.
- Zhejiang Taimei offers TrialOS and PharmaOS for pharmaceutical R&D and commercialization.
- Zhejiang Taimei provides SaaS products and digital clinical research services.
Weaknesses
- Zhejiang Taimei's business is limited to domestic and overseas markets in China.
- Zhejiang Taimei has no mention of international expansion plans beyond China.
- Zhejiang Taimei's digital services lack specific market share data.
Opportunities
- Zhejiang Taimei can expand its cloud-based software services globally.
- Zhejiang Taimei can leverage its SaaS products for international pharmaceutical companies.
- Zhejiang Taimei can grow its digital clinical research services in emerging markets.
Threats
- Zhejiang Taimei faces competition from domestic Chinese competitors in Life Sciences Tools & Services.
- Zhejiang Taimei must comply with evolving regulations in the Health Care sector.
- Zhejiang Taimei's reliance on digital solutions may face technological disruption.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.